Efpeglenatide

• In people with diabetes, all digestive adverse events with efpeglenatide were mild or moderate and temporary. (BMJ open diabetes research & care, 2021)
• In high-risk participants with diabetes, diarrhea, constipation, nausea, vomiting, or bloating occurred more often with efpeglenatide than with placebo. (The New England journal of medicine, 2021)
• In people with early diabetes, nausea with efpeglenatide rapidly subsided after the initial 2 weeks. (Diabetes care, 2019)
• In adults without diabetes, adverse events caused 5% to 19% of efpeglenatide recipients to stop the study. (Diabetes, obesity & metabolism, 2019)
• In adults with diabetes, digestive adverse events were most common with efpeglenatide and generally temporary and mild or moderate. (Diabetes care, 2022)
• In patients with diabetes, digestive disorders were the most common adverse events during efpeglenatide treatment. (Diabetes, obesity & metabolism, 2020)
• In patients with diabetes, efpeglenatide was generally well tolerated in both studies. (Diabetes, obesity & metabolism, 2020)
• In AMPLITUDE-D, low blood sugar affected few people across all groups, including efpeglenatide. (Diabetes, obesity & metabolism, 2023)
• Across patient subgroups, digestive adverse events were the most common adverse events with efpeglenatide. (BMJ open diabetes research & care, 2022)
• In people with early diabetes, vomiting with efpeglenatide rapidly subsided after the initial 2 weeks. (Diabetes care, 2019)
• In people with early diabetes, no neutralizing antibodies were detected with efpeglenatide. (Diabetes care, 2019)
• In adults without diabetes, digestive effects were the most common adverse events during efpeglenatide treatment. (Diabetes, obesity & metabolism, 2019)
• In adults with diabetes receiving efpeglenatide, few patients reported low blood sugar. (Diabetes care, 2022)
• In patients with diabetes, digestive disorders were the most frequently reported adverse events during efpeglenatide treatment. (Diabetes, obesity & metabolism, 2020)
• In AMPLITUDE-L, low blood sugar affected few people across all groups, including efpeglenatide. (Diabetes, obesity & metabolism, 2023)
• In AMPLITUDE-S, low blood sugar affected few people across all groups, including efpeglenatide. (Diabetes, obesity & metabolism, 2023)
• In people with diabetes receiving efpeglenatide, digestive adverse events were the most frequent adverse events across the trials. (Diabetes, obesity & metabolism, 2023)

The doses that these studies used. They are not recommendations.